Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 19;54(12):1-22.
doi: 10.1159/000547477. Online ahead of print.

Current Knowledge on the Impact of Extracorporeal Blood Purification Devices on Drug Clearance - Systematic Search & Narrative Review

Rajib Paul, Abdul Samad Ansari, David Ballesteros, Teresa Klaus, Patrick M Honoré

Current Knowledge on the Impact of Extracorporeal Blood Purification Devices on Drug Clearance - Systematic Search & Narrative Review

Rajib Paul et al. Blood Purif. .

Abstract

Introduction Extracorporeal blood purification (EBP) devices are increasingly used in critically ill patients to manage sepsis, hyperinflammatory states, and other life-threatening conditions. However, these devices may unintentionally remove therapeutic medications, potentially compromising efficacy. Understanding these interactions is essential to optimize therapy and ensure patient safety. Methods A systematic search of PubMed, Cochrane, and manufacturer-specific databases was performed to identify literature on drug removal by current adsorptive EBP devices. Studies were screened for evidence of drug clearance, including both preclinical and clinical (in-vivo) data, using specific keywords related to drug removal and therapeutic drug monitoring (TDM). Results Out of 659 identified articles, 61 met the inclusion criteria. CytoSorb was the most extensively studied device, with 25 relevant publications-19 of which included in-vivo data. Data on drug removal were found for 43 substances with CytoSorb, 8 with Jafron, 12 with oXiris, 25 with Seraph, and 13 with PMX-HP. Antibiotics were the most commonly studied drug class, with vancomycin and meropenem being the most frequently investigated agents. While CytoSorb had the most comprehensive data, evidence for other devices was limited, especially regarding clinical studies. Conclusions Adsorptive EBP devices have the potential to unintentionally remove medications, which may compromise therapeutic effectiveness in critically ill patients if not properly accounted for. Among currently available devices, CytoSorb has the most comprehensive evidence base. However, additional clinical studies are required for all devices to confirm findings and establish dosing recommendations. The use of therapeutic drug monitoring, when available, is strongly advised to guide clinical decision-making. .

PubMed Disclaimer

Conflict of interest statement

Patrick M. Honoré was a member of the journal’s Editorial Board at the time of submission and received some grants for CytoSorbents. Teresa Klaus is full-time employee of CytoSorbents Europe GmbH. All other authors declare no conflict of interest. While one author is employed by CytoSorbents Europe GmbH, all efforts were made to ensure a balanced, evidence-based interpretation of the data. The inclusion and discussion of CytoSorb and other devices were based solely on the volume and quality of available literature, as outlined in the Methods section. The manuscript was co-authored and reviewed by independent researchers with no affiliation to the manufacturer.

Figures

Fig. 1.
Fig. 1.
Total identified articles from key word search.
Fig. 2.
Fig. 2.
Percentage of total identified articles for different devices.
See this image and copyright information in PMC

References

    1. Monaghan KN, Acierno MJ. Extracorporeal removal of drugs and toxins. Vet Clin North Am Small Anim Pract. 2011;41(1):227–38. - PubMed
    1. Roberts JA, Joynt GM, Lee A, Choi G, Bellomo R, Kanji S, et al. The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational sampling antibiotics in renal replacement therapy study. Clin Infect Dis. 2021;72(8):1369–78. - PubMed
    1. Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med. 2014;42(8):1749–55. - PubMed
    1. Roberts DM, Liu X, Roberts JA, Nair P, Cole L, Roberts MS, et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care. 2015;19:84. - PMC - PubMed
    1. Morales Castro D, Dresser L, Granton J, Fan E. Pharmacokinetic alterations associated with critical illness. Clin Pharmacokinet. 2023;62(2):209–20. - PMC - PubMed

Publication types